Sunday, February 11, 2018

Opioids and pharma sales

Prescription pain medicines have played a significant role in the opioid epidemic.  Recently, the makers of OxyContin have decided to stop direct marketing it to doctors. Stat has the story:
End of an era: Purdue to stop marketing opioids to doctors

"Purdue Pharmaceuticals, the maker of the opioid painkiller OxyContin, said it would no longer actively market opioid products — a major about-face for a company increasingly viewed as a principal culprit in the country’s addiction and overdose crisis.
The company said it is reducing its sales staff by more than half, and that its remaining salespeople will no longer visit doctor’s offices to push their product. Instead, the company said it will direct prescribers to materials published by the Centers for Disease Control and Prevention and the office of the U.S. surgeon general.
...
"The health insurer Cigna also announced in October it would no longer cover OxyContin through employer-based plans, shortly after the pharmaceutical industry lobby group PhRMA broadly endorsed policies that limit opioid prescriptions to seven days."

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.